The North African Journal of Scientific Publishing (NAJSP)
مجلة شمال إفريقيا للنشر العلمي (NAJSP)
E-ISSN: 2959-4820
Volume 3, Issue 1, January - March 2025
Page No: 221-232
Website: https://najsp.com/index.php/home/index
SJIFactor 2024: 5.49 **0.71 :2024 (AIF) معامل التأثير العربي** **ISI 2024: 0.696**

Advancements in Photodynamic Therapy for Nonmelanoma Skin Cancers

Hana Alazoumi Abdulsalam [1*], Tibrah Misbah Mohammed [2], Suad Ali Uneis [3], Sumia Abdallah Almukhtar [4], Ahmed Mohammed Alqeeb [5]
[1] Chemistry Department, Faculty of Education, University of Gharyan, Gharyan, Libya
[2,4,5] Chemistry Department, Faculty of Education, Azzaytuna University, Tarhuna, Libya
[3]Chemistry Department, Faculty of Science, Azzaytuna University, Tarhuna, Libya

التطورات في العلاج الضوئي الديناميكي لسرطانات الجلد غير الميلانينية

هناء العزومي عبد السلام [1*]، تبرة مصباح محمد [2]، سعاد علي ونيس [3]، سمية عبدالله المختار [4]،احمد محمد القيب [5]
[1] قسم الكيمياء، كلية التربية، جامعة غريان، الزاوية، ليبيا
[2،4،5] قسم الكيمياء، كلية التربية، جامعة الزيتونة، ترهونة، ليبيا
[3] قسم الكيمياء، كلية العلوم، جامعة الزيتونة، ترهونة، ليبيا

*Corresponding author: hanakashakah@gmail.com

Received: January 18, 2025	Accepted: March 06, 2025	Published: March 22, 2025

Abstract:
Photodynamic therapy (PDT) is a minimally invasive therapeutic modality that employs a light-activated chemical reaction to selectively destroy pathological tissue. This reaction relies on three essential components: a photosensitizing agent, a light source emitting within the agent's absorption spectrum, and the presence of molecular oxygen. Among the most widely studied and clinically approved photosensitizers are 5-aminolevulinic acid (ALA), primarily used for actinic keratosis (AK), and methyl aminolevulinate (MAL), approved for the treatment of AK, basal cell carcinoma (BCC), and Bowen's disease. Light-emitting diode (LED) sources have become standard in PDT due to their wavelength specificity and safety profile, particularly in the treatment of nonmelanoma skin cancers. PDT offers significant therapeutic advantages in patients with superficial, multiple, or widespread lesions, and has demonstrated particular benefit in immunocompromised individuals who may not tolerate invasive procedures. Beyond oncologic indications, recent advancements have extended PDT applications to various inflammatory and infectious dermatological conditions, including photoaging, acne vulgaris, hidradenitis suppurativa, psoriasis, viral warts, scleroderma, and cutaneous leishmaniasis. This article presents a comprehensive review of the underlying mechanisms of photodynamic therapy, its clinical indications, therapeutic outcomes, and future potential in dermatological practice.

Keywords: Photodynamic Therapy (PDT), Photosensitizer, Nonmelanoma Skin Cancer, Reactive Oxygen Species (ROS), Dermatological Applications.

الملخص

العلاج الضوئي الديناميكي (*PDT*) هو أسلوب علاجي طفيف التوغل يعتمد على تفاعل كيميائي يُفعّل بواسطة الضوء ويُستخدم لتدمير الأنسجة المرضية بشكل انتقائي. يعتمد هذا التفاعل على ثلاثة عناصر أساسية: عامل تحسّس ضوئي، ومصدر ضوء يصدر أطوال موجية ضمن نطاق امتصاص العامل، ووجود الأكسجين الجزيئي. من بين العوامل الضوئية الأكثر دراسة واعتمادًا سريريًا حمض 5-أمينوليفولينيك (*ALA*)، المستخدم بشكل رئيسي لعلاج التقران السفعي (*AK*)، وميثيل أمينوليفولينات (*MAL*)، المعتمد لعلاج التقران السفعي، وسرطان الخلايا القاعدية (*BCC*)، وداء بوين. أصبحت مصادر الضوء المعتمدة على الثنائيات الباعثة للضوء (*LED*) معيارًا في العلاج الضوئي الديناميكي نظرًا لخصوصية أطوالها الموجية وملف الأمان الخاص بها، لا سيما في علاج سرطانات الجلد غير الميلانومية. ويوفّر هذا العلاج مزايا علاجية ملحوظة لدى المرضى الذين يعانون من آفات سطحية، متعددة أو منتشرة، وقد أثبت فعالية خاصة لدى المرضى المثبّطي المناعة الذين قد لا يتحمّلون الإجراءات الجراحية. وبالإضافة إلى استخداماته في علاج الأورام، فقد توسعت تطبيقات العلاج الضوئي الديناميكي مؤخرًا لتشمل مجموعة من الأمراض الجلدية الالتهابية والمعدية، مثل: شيخوخة الجلد الناتجة عن التعرض للشمس، حب الشباب، التهاب الغدد العرقية القيحي، الصدفية، الثآليل الفيروسية، تصلب الجلد، وداء الليشمانيا الجلدية. يقدم هذا المقال مراجعة شاملة لآليات عمل العلاج الضوئي الديناميكي، ودواعي استخدامه السريرية، ونتائجه العلاجية، وآفاقه المستقبلية في الممارسة الجلدية.

الكلمات المفتاحية: العلاج الضوئي الديناميكي (*PDT*)، العامل المحسس للضوء، سرطان الجلد غير الميلانومي، أنواع الأكسجين التفاعلية (*ROS*)، التطبيقات الجلدية.

Introduction

Cutaneous disorders often arise from intricate interactions between environmental factors, particularly light exposure, and various chemical compounds. Among therapeutic modalities that exploit this interaction, PUVA (psoralen plus ultraviolet A radiation) therapy stands out as a well-established form of photochemotherapy, effectively used in managing several dermatological conditions such as psoriasis and vitiligo [1-4]. However, a more refined and targeted therapeutic approach has emerged in recent decades, Photodynamic Therapy (PDT). PDT is a minimally invasive treatment modality that relies on the synergistic interaction between a photosensitizing agent, an appropriate wavelength of light, and molecular oxygen to generate cytotoxic reactive oxygen species (ROS) [5,6]. This photochemical reaction selectively induces cellular damage in pathological tissues while sparing the surrounding healthy cells. The selectivity of PDT is attributed to the preferential accumulation of photosensitizers in diseased cells, and the precise targeting achievable with controlled light exposure [7-9].

Among the most commonly used photosensitizers in dermatology are 5-aminolevulinic acid (ALA) and its more lipophilic derivative, methyl aminolevulinate (MAL). These agents act as precursors in the heme biosynthesis pathway, leading to intracellular accumulation of protoporphyrin IX, a potent photosensitizing molecule [10-12]. Upon activation by red or blue light in the presence of oxygen, these molecules generate singlet oxygen and other ROS that induce apoptosis or necrosis in target cells. Initially introduced for the treatment of superficial malignancies, PDT has gained significant traction in dermatologic oncology for managing nonmelanoma skin cancers, such as actinic keratosis (AK), superficial basal cell carcinoma (sBCC), and Bowen's disease. The non-invasive nature of PDT allows for the treatment of multiple lesions across large surface areas, with minimal tissue disruption, making it particularly advantageous for cosmetically sensitive areas such as the face and scalp [13-15].

In addition to its oncologic applications, growing evidence suggests that PDT holds therapeutic potential for various non-neoplastic dermatological conditions, including acne vulgaris, viral warts, and photoaging-associated dermatoses. Its utility in photoaged skin lies in its ability to remodel dermal collagen and elastin fibers, enhance epidermal turnover, and reduce pigmentation irregularities, features that are particularly relevant in aesthetic dermatology. Furthermore, PDT is associated with a favorable safety profile, low systemic toxicity, and excellent cosmetic outcomes. Recovery times are typically short, and the risk of scarring is minimal when compared to surgical interventions. These attributes make PDT an increasingly preferred treatment, particularly for patients seeking effective yet cosmetically acceptable therapies [16-19]. Despite its advantages, PDT is not without limitations. Treatment efficacy can be influenced by factors such as lesion thickness, depth of photosensitizer penetration, oxygen availability, and patient adherence to post-treatment photoprotection protocols. Ongoing research aims to optimize photosensitizer formulations, light delivery systems, and combination therapies to enhance clinical outcomes and broaden the scope of indications for PDT.

Background

Photodynamic therapy (PDT) is a treatment modality characterized by a photochemical reaction designed to selectively destroy targeted tissues. This therapeutic approach typically involves a two-stage process: the administration of a photosensitizing agent, either topically, systemically, or by instillation, followed by irradiation with a specific wavelength of visible light. Upon activation by light, the photosensitizers, whether exogenously administered or endogenously produced, transfer energy to molecular oxygen. This energy transfer generates reactive oxygen species (ROS), particularly singlet oxygen ($1O^2$), which induces cytotoxic effects leading to cell death [19,20].

The route of photosensitizer administration varies depending on the tumor location. For instance, oral or intravenous administration is commonly used for gastrointestinal, brain, and bronchopulmonary tumors. In contrast, intravesical instillation is typically employed for bladder or endometrial cancers, while topical application is effective for cutaneous malignancies [20-23].

PDT, often referred to as photochemotherapy, is distinguished from other light-induced processes by its requirement for oxygen involvement. The term "photodynamic action" was originally introduced to denote photosensitized reactions in biological systems that involve oxygen consumption, differentiating it from physicochemical reactions found in photographic emulsions. These processes are further categorized as type I or type II photosensitized reactions. Type I reactions involve the formation of radical intermediates that subsequently interact with oxygen, whereas type II reactions involve the direct generation of singlet oxygen ($1O^2$) through energy transfer from the excited photosensitizer. Due to its high reactivity, singlet oxygen has a very short half-life (<0.04 µs) and an extremely limited diffusion radius (<0.02 µm) in biological environments, which confines its cytotoxic action to a highly localized area [24-26].

Modern PDT research and applications trace their origins to the work of R.L. Lipson and S. Schwartz at the Mayo Clinic in the 1960s. They observed that injections of crude hematoporphyrin solutions caused fluorescence in neoplastic lesions during surgery. To enhance tumor selectivity, Schwartz chemically modified hematoporphyrin using acetic and sulfuric acid, producing a complex mixture of porphyrins known as hematoporphyrin derivative (HPD), which Lipson and colleagues subsequently employed for tumor detection. HPD comprises a range of porphyrin monomers, dimers, and oligomers. It has since been partially refined to eliminate fewer active monomers, resulting in the formulation of Photofrin®, the most widely used photosensitizer in clinical PDT. Figure 1 illustrates Hematoporphyrin Structure [26-28]. Figure 2 presents Photofrin Structure.



Figure 1: Hematoporphyrin Structure.



Figure 2: Photofrin Structure.

Despite its clinical utility, Photofrin has limitations, particularly its long-lasting skin phototoxicity and restricted light absorption spectrum (maximum ~640 nm), which limits tissue penetration. To address these issues, several next-generation photosensitizers with higher absorbance in the 650–850 nm range have been developed and are currently under clinical evaluation.

Future Directions of Photodynamic Therapy (PDT)

The future of photodynamic therapy (PDT) is poised for significant expansion, driven by the emergence of novel photosensitizing agents developed by various pharmaceutical enterprises. These next-generation photosensitizers not only enhance the efficacy of PDT for malignancies traditionally treated with first-generation agents like Photofrin but also broaden the therapeutic scope to encompass a wider range of clinical conditions. For instance, benzoporphyrin derivative monoacid ring A (BPD-MA) has demonstrated potential in the treatment of age-related macular degeneration (AMD) and may be further explored for managing inflammatory disorders such as rheumatoid arthritis. Similarly, agents such as tin ethyl etiopurpurin (SnET2) and meta-tetra(hydroxyphenyl)chlorin (mTHPC) have shown promise in the treatment of prostatic pathologies, while topical applications of 5-aminolevulinic acid (ALA) or its methyl ester (MAL) continue to evolve as effective options for superficial dermatological lesions. Moreover, preliminary investigations suggest a potential role for PDT in the treatment of cardiovascular diseases, including coronary artery conditions, marking a significant paradigm shift in its interdisciplinary application [29-31].

Despite these advances, a key challenge remains the broader acceptance and integration of PDT into mainstream clinical practice. Physician adoption has been relatively slow, hindered in part by a steep learning curve associated with understanding PDT protocols and managing treatment-specific adverse effects, particularly phototoxic reactions in non-target tissues due to inadvertent photosensitizer accumulation. To address this gap, several academic and clinical centers have initiated specialized training programs and workshops. Institutions such as the University of Louisville (Kentucky, USA), Grant Medical Center (Columbus, Ohio), and the Royal London Hospital (United Kingdom) have played pivotal roles in offering structured educational programs aimed at enhancing clinician familiarity and competence with PDT [30-32].

Technological advancements are also instrumental in mitigating the barriers to widespread implementation. Traditional PDT protocols often necessitate the use of expensive, complex light sources. However, the development and increasing availability of cost-effective diode lasers tailored for both existing and emerging photosensitizers offer a practical solution. These compact, wavelength-specific lasers can deliver targeted illumination with precision, improving therapeutic outcomes while reducing collateral tissue damage [33,34]. Additionally, pharmaceutical companies and biomedical engineers are collaborating closely to refine treatment protocols and enhance device-user compatibility. Ongoing innovations aim to reduce systemic photosensitization, improve selective uptake of photosensitizers in diseased tissues, and enhance light delivery mechanisms. Such interdisciplinary efforts are pivotal in building clinical confidence in PDT, underscoring its utility through evidence-based practice and reproducible outcomes.

Application Technique

Proper preparation of the skin is essential for the success and efficacy of photodynamic therapy (PDT). The procedure begins with meticulous cleansing of the treatment area. This is performed using cotton wool soaked in a soap-free cleansing solution, followed by disinfection with gauze impregnated with alcohol. Once the area is cleansed, superficial debridement of the lesion is carried out using a curette to remove crusts or hyperkeratotic tissue, which enhances photosensitizer penetration. Any resultant bleeding is managed by applying gentle pressure using dry sterile gauze [35-37]. Following hemostasis, the photosensitizing agent is applied directly to the lesion as illustrated Figure 3. Two commonly used photosensitizers are:

- 5-aminolevulinic acid (ALA), commercially available in Brazil under the trade name Levulan® in a stick formulation prepared immediately before application, and
- Methyl aminolevulinate (MAL), available as a pre-prepared cream marketed under the name Metvix®.

The incubation period of the photosensitizer is governed by established clinical protocols. For MAL-PDT, a uniform layer approximately 1 mm thick is applied over the lesion, with an additional safety margin of 5–10 mm beyond the visible edges. The treated area is then occluded with a plastic dressing for three hours to facilitate absorption. To shield the area from ambient light during incubation, which

may inadvertently activate the photosensitizer, aluminum foil is placed over the plastic occlusion as presented Figure 4.

After the incubation period, the photosensitizer is gently removed using dry gauze or a saline rinse. The light activation phase follows, where parameters such as wavelength, energy dosage, and exposure time are determined based on the selected light source. According to standard MAL-PDT protocols, red light at 635 nm is employed, delivering a total fluence of 37 J/cm². For actinic keratosis (AK), a single MAL-PDT session is generally sufficient. However, a second session may be conducted three months later if needed. In cases of basal cell carcinoma (BCC) or Bowen's disease, two treatment sessions are typically recommended, spaced one week apart [37-40].



Figure 3: Administration of Methyl Aminolevulinate onto the Lesion Utilizing a Wooden Spatula.

Figure 4: Shielding of the Photosensitizer with a Plastic Dressing and Aluminum Foil to Safeguard It from Light Exposure.

For ALA-PDT, protocols may vary significantly, particularly with respect to incubation time, which can range from 30 minutes to 18 hours, with or without occlusion. Additionally, diverse light sources can be used for light activation in ALA-based treatments. Post-procedural care includes strict photoprotection, both chemical (e.g., sunscreens) and physical (e.g., protective clothing), to prevent phototoxic reactions due to residual photosensitizer in the skin.

Clinical Indications

Actinic Keratosis (AK)

Photodynamic therapy (PDT) has been officially approved by the U.S. Food and Drug Administration (FDA) for the treatment of actinic keratosis (AK) since 1999. AK is a common precancerous skin condition caused by chronic sun exposure, particularly affecting fair-skinned individuals. PDT offers a non-invasive and effective therapeutic option with favorable cosmetic outcomes, especially for patients presenting with multiple lesions in sun-exposed areas. Topical PDT for AK generally achieves cure rates ranging from 73% to 100%, as reported in various clinical studies (Figures 5 and 6). These outcomes are comparable to those achieved with conventional treatments such as cryotherapy, but with the added advantages of fewer side effects, reduced discomfort, and shorter recovery times [41-44].



Figure 5: Pretreatment (MAL-PDT) Of an Area of Actinic Keratosis on the Hemiface.



Figure 6: Area of Actinic Keratosis on the Hemi Face after Three Months of Treatment (MAL_PDT).

Initial clinical trials using ALA-based PDT with blue light involved long incubation periods of 14 to 18 hours prior to light exposure. However, subsequent studies have demonstrated that significantly shorter incubation times, less than three hours, and even as brief as 30 to 60 minutes, do not compromise the

safety or efficacy of the treatment. These findings have enhanced the practicality and patient compliance associated with PDT protocols. Comparative studies have shown that methyl aminolevulinate (MAL) exhibits superior penetration into neoplastic tissue compared to ALA, potentially enhancing therapeutic outcomes.

Basal Cell Carcinoma (BCC)

Basal cell carcinoma (BCC) is the most prevalent form of malignant skin tumor, accounting for approximately 70% of nonmelanoma skin cancers in adults. The choice of treatment for BCC depends on various factors, including the histological subtype, tumor size, depth, and anatomical location. Conventional therapeutic modalities include surgical excision, curettage with electrocoagulation, cryotherapy, topical immunomodulators, cytotoxic agents, and radiotherapy. In recent years, photodynamic therapy (PDT) has emerged as a non-invasive alternative for the treatment of selected cases of BCC. PDT is particularly advantageous in cosmetically sensitive areas or for patients who are not ideal candidates for surgery. However, the efficacy of PDT is significantly influenced by tumor thickness, given the limited penetration depth of the activating light source. Therefore, lesions exceeding 2–3 mm in depth are generally less responsive to PDT, and complete eradication is less likely [45-47].

Comparative studies indicate that ALA-PDT has shown limited efficacy in the treatment of BCC, potentially due to lower tissue selectivity and penetration. In contrast, methyl aminolevulinate (MAL) has demonstrated superior clinical outcomes. This may be attributed to MAL's enhanced lipophilicity, which improves its selectivity for tumor cells and allows for greater tissue penetration. PDT with MAL, when combined with red light irradiation (typically 635 nm), has achieved clearance rates of up to 95% for superficial BCC and 73% to 94% for nodular BCC. These response rates make MAL-PDT a compelling option, particularly for superficial lesions [46-48].

However, recurrence rates remain a critical factor in evaluating long-term efficacy. For superficial BCC treated with MAL-PDT, the recurrence rate is approximately 22%, which is comparable to that observed with cryotherapy (~19%). In contrast, for nodular BCC, the recurrence rate following MAL-PDT is about 14%, which is significantly higher than that of surgical excision, the standard of care, which yields recurrence rates as low as 4%. Numerous studies have emphasized the key advantages of photodynamic therapy (PDT) in the management of nonmelanoma skin cancers, particularly in cases where conventional therapies may not be ideal. Among the most notable benefits are the significantly reduced recovery time, excellent cosmetic outcomes, and high cure rates, with recurrence rates comparable to those reported for alternative treatments such as surgical excision, cryotherapy, and topical chemotherapeutics [49,50].

PDT has shown particular value in specific clinical scenarios, including the management of multiple lesions, especially in elderly or immunocompromised patients, and in cases where surgery is contraindicated due to comorbidities or anatomical considerations. Additionally, PDT is especially advantageous for treating lesions located in areas with poor wound healing potential, such as the lower extremities (Figures 7 and 8).



Figure 7: Pretreatment (MAL_PDT) of a Superficial Basal Cell Carcinoma Lesion on the Lower Extremity.



Figure 8: Twelve-Month Follow-Up of the Superficial Basal Cell Carcinoma Lesion Treated with MAL-PDT.

According to international consensus guidelines on the application of PDT for nonmelanoma skin cancers, methyl aminolevulinate-based PDT (MAL-PDT) is recommended as an effective first-line treatment for superficial basal cell carcinoma (sBCC), particularly in cases involving extensive or multiple lesions where surgical intervention may be less practical or pose a greater risk of scarring and functional impairment.

Moreover, PDT has demonstrated efficacy in the treatment of Bowen's disease (squamous cell carcinoma in situ), with clinical studies reporting results that are comparable or superior to those

obtained with cryotherapy or topical 5-fluorouracil. When appropriately indicated and carefully administered, MAL-PDT has also shown sustained therapeutic effectiveness in nodular BCC [51-53]. These findings support the inclusion of PDT, particularly MAL-PDT, as a valuable, evidence-based option in the multidisciplinary management of nonmelanoma skin cancers, offering a combination of efficacy, safety, and aesthetic superiority.

PDT and ROS

Photodynamic therapy (PDT) is a minimally invasive therapeutic approach that relies on three key components: a photosensitizer (PS), a specific light source, and molecular oxygen. Figure 9 presents ROS Generation via Oxidation. Upon light activation at a wavelength specific to the PS (e.g., 635 nm for methylene blue or MAL), reactive oxygen species (ROS) are generated, including singlet oxygen (1O2) and free radicals such as hydroxyl radicals (•OH) and superoxide anions (O_2•⁻). These ROS induce oxidative damage to cellular components, ultimately leading to cell death through apoptosis, necrosis, or autophagy. The experiments conducted in this study collectively aim to demonstrate the generation and biological consequences of ROS through various physical, chemical, and biological indicators.



Figure 9: ROS Generation via Oxidation.

ROS Generation via KI Oxidation

This experiment exploits the well-established ability of ROS to oxidize iodide ions (I^-) into iodine (I_2), resulting in a visible brown coloration. The presence of methylene blue, acting as a photosensitizer, and the requirement for light exposure confirm that ROS are formed through a photodynamic process. The control sample, kept in the dark, showed no color change, reaffirming that the observed oxidation is light-dependent and mediated by the photosensitizer. This simple yet powerful assay illustrates a qualitative detection of ROS and serves as a model for demonstrating oxidative stress mechanisms in a controlled setting. It mirrors the oxidative reactions that occur in biological tissues during PDT.

pH Monitoring During PDT

A drop in pH from neutral (7.0) to acidic (6.0) after light exposure is attributed to the generation of acidic species, such as hydrogen peroxide (H_2O_2) and organic acid byproducts, during ROS-mediated reactions. Figure 10 illustrates pH changes during light exposure (PDT Simulation). This experiment offers a semi-quantitative indicator of ROS activity. The lack of significant pH change in the dark control validates that acid formation was due to photodynamically induced processes rather than spontaneous oxidation. This pH shift is also physiologically relevant, as local acidification can promote cellular damage and influence enzyme activity and drug efficacy during PDT treatment.



Figure 10: pH changes during light exposure (PDT Simulation).

Dye Photobleaching Observation

Photobleaching refers to the irreversible breakdown of dye molecules upon prolonged light exposure in the presence of oxygen. The observed fading of methylene blue over time indicates that ROS are not only damaging to cellular structures but also to the photosensitizer itself. This experiment demonstrates the self-limiting nature of PDT due to photosensitizer degradation, which can impact treatment efficacy if not properly managed. The kinetics of photobleaching can inform dosimetry optimization, helping to determine optimal irradiation times that balance efficacy with minimal PS depletion. Figure 11 shows Dye Photobleaching over time.



Figure 11: Dye Photobleaching over time.

UV-Vis Absorption Analysis

Spectrophotometric data showed decreased absorbance in characteristic peaks (e.g., ~660 nm for methylene blue), consistent with photochemical degradation of the photosensitizer. This is a quantitative confirmation of the photobleaching process observed visually in the previous experiment. These spectral changes not only validate the ROS-mediated decomposition of the dye but also provide insights into light penetration depth, PS stability, and absorption efficiency, critical parameters for tailoring PDT protocols in clinical settings. Figure 12 demonstrates simulated UV-Vis absorption of photosensitizer.



Figure 12: Simulated UV-Vis absorption of photosensitizer.

PDT Effects on Microbial Growth

The antimicrobial PDT experiment represents a biological validation of ROS cytotoxicity. Figure 13 presents realistic PDT Effect on Microbial Culture. The significant inhibition of bacterial growth in the PDT+Light group, compared to other groups (light only, dye only, and control), confirms that ROS production under illumination is essential for antimicrobial efficacy as presented in Figure 14. This model simulates how PDT can be used for localized infections, such as chronic wounds, dental plaque, or antibiotic-resistant strains. The synergistic role of dye and light provides a foundation for non-antibiotic-based therapies, especially relevant in an era of rising antimicrobial resistance.

Figure 13: Realistic PDT Effect on Microbial Culture.



Figure 14: Effect of PDT on Microbial growth.

Temperature Dependence of PDT

Reaction efficiency was highest at 37°C, the temperature closest to physiological conditions. At lower temperatures (15°C and 25°C), ROS generation was visibly reduced, likely due to slower diffusion rates and reduced molecular collisions. This finding has important clinical implications: maintaining optimal tissue temperature during PDT could enhance treatment efficacy. Figure 15 illustrates effect of temperature on PDT reaction intensity. In contrast, excessively high temperatures may lead to thermal damage or alter PS behavior. Thus, thermal regulation is a modifiable variable in optimizing PDT outcomes.



Figure 15: Effect of temperature on PDT reaction intensity.

General Implications and Limitations

- ROS selectivity: While ROS are cytotoxic to target cells, their very short lifespan and limited diffusion range (<0.02 μm for $1O^2$) provide spatial specificity, limiting collateral damage to surrounding healthy tissue.
- Light penetration: The effectiveness of PDT is inherently limited by the penetration depth of light into tissues (~2–3 mm for red light). Thus, PDT is better suited for superficial lesions or when combined with fiber optic delivery in deeper sites.
- Photosensitizer limitations: As shown, photobleaching reduces the available concentration of PS over time. Using PSs with better photostability or controlled release systems can enhance long-term efficacy.
- Translational relevance: These model experiments offer scalable insights, from bench to bedside, by illustrating key mechanisms that underlie clinical PDT for dermatological, oncological, and antimicrobial applications.

Conclusion

The experimental series conducted in this study effectively illustrates the fundamental principles and therapeutic potential of photodynamic therapy (PDT). Through diverse assays, including KI oxidation, pH monitoring, dye photobleaching, UV-Vis absorption analysis, microbial inhibition, and temperature variation, the data consistently confirm the generation of reactive oxygen species (ROS) upon light activation of methylene blue. The formation of iodine, reduction in pH, degradation of the

photosensitizer, and significant suppression of microbial growth in PDT-treated groups collectively validate the central role of ROS in PDT-mediated cytotoxicity. Additionally, the influence of temperature and environmental conditions emphasizes the importance of optimizing physical parameters for maximal therapeutic efficacy. These findings support the application of PDT in both chemical and biomedical contexts, such as antimicrobial treatment and potentially cancer therapy, provided that light delivery, photosensitizer formulation, and tissue characteristics are carefully tailored. PDT is therefore reaffirmed as a promising, minimally invasive strategy with broad applications, especially in an era that demands innovative solutions to drug resistance and precision-targeted therapies.

Future Recommendations

To further advance the capabilities and clinical application of PDT, the following recommendations are proposed:

- Development of Novel Photosensitizers:
  Investigate next-generation photosensitizers with improved selectivity, reduced phototoxicity, and enhanced absorption in the near-infrared (NIR) region for deeper tissue penetration.
- Integration with Nanotechnology:
  Explore nanocarrier systems (e.g., liposomes, nanoparticles) to enhance targeted delivery, improve bioavailability, and facilitate controlled intracellular release of photosensitizers.
- Broadening Biological Evaluation:
  Extend PDT trials to diverse microbial species and cancer cell lines to assess its therapeutic versatility and spectrum of activity.
- Multimodal Therapy Approaches:
  Evaluate synergistic effects by combining PDT with chemotherapy, radiotherapy, or immunotherapy, potentially enhancing overall therapeutic outcomes.

To enhance the effectiveness and clinical adoption of photodynamic therapy (PDT), future research should focus on developing advanced photosensitizers with improved selectivity and deeper tissue penetration, and leveraging nanotechnology for targeted drug delivery. Expanding the scope of PDT to various microbial strains and cancer types will help assess its therapeutic versatility. Integrating PDT with other treatment modalities such as chemotherapy and immunotherapy may offer synergistic benefits. Innovations in light delivery systems and real-time ROS monitoring can improve precision and control. Evaluating long-term safety, optimizing PDT for low-resource settings, and accounting for factors like oxygen availability and repeated exposures are essential for broader clinical application. Personalized PDT protocols tailored to individual patient and tissue characteristics will further advance treatment efficacy and outcomes.

References

[1] M. G. Danieli, C. Mezzanotte, A. Paladini, D. Benfaremo, G. Murdaca, and G. Moroncini, “Hypogammaglobulinemia in patients affected by limited cutaneous systemic sclerosis: Case series and review of the literature,” *J. Scleroderma Relat. Disord.*, p. 23971983251333851, 2025.

[2] A. J. Jafari, M. Rivera, and A. A. Hebert, “The role of thymic stromal lymphopoietin in cutaneous disorders,” *Arch. Derm. Res.*, vol. 316, no. 5, p. 123, 2024.

[3] W. Kempf *et al.*, “Classifications of cutaneous lymphomas and lymphoproliferative disorders: An update from the EORTC cutaneous lymphoma histopathology group,” *J. Eur. Acad. Dermatol. Venereol.*, vol. 38, no. 8, pp. 1491–1503, 2024.

[4] R. Willemze, “Cutaneous lymphoproliferative disorders: Back to the future,” *J. Cutan. Pathol.*, vol. 51, no. 6, pp. 468–476, 2024.

[5] C. Xiao, X. Xu, Y. Lin, H. Kang, and H. Zhang, “Clinical efficacy of 5-aminolevulinic acid photodynamic therapy combined with microneedling for vulvar lichen sclerosus,” *Photodiagnosis Photodyn. Ther.*, vol. 53, no. 104623, p. 104623, 2025.

[6] Y. Mao, H. Chen, Y. Tang, H. Geng, and F. Zhang, “Optical coherence tomography angiography study on retinochoroidal thickness and blood flow changes after posterior scleral reinforcement surgery,” *Photodiagnosis Photodyn. Ther.*, vol. 53, no. 104628, p. 104628, 2025.

[7] B. Bolhari, N. Meraji, R. Seddighi, Y. Safaraei, and N. Chiniforush, “In vitro effects of laser-activated irrigation methods on apical extrusion of indocyanine green mediated photodynamic therapy,” *Photodiagnosis Photodyn. Ther.*, vol. 53, no. 104626, p. 104626, 2025.

[8] S. Vaccari, A. N. Rossi, F. Pepe, F. Cassini, M. Roda, and E. Dika, “Palpebral Bowen’s disease: a report of two cases successfully treated with photodynamic therapy,” *Photodiagnosis Photodyn. Ther.*, vol. 53, no. 104622, p. 104622, 2025.

[9] Z.-X. Chen, H. Chen, H. Wei, L. Chen, and G.-Q. Shi, “Surgery combined with endoscopic photodynamic therapy for simultaneous double primary early carcinomas of the esophagus and cardia: a case report,” *Photodiagnosis Photodyn. Ther.*, vol. 53, no. 104616, p. 104616, 2025.

[10] R. Nienstedt, B. Schlagenhauff, and B. C. Rümmelein, “Treatment of therapy-resistant verruca plantaris with laser-assisted photodynamic therapy (PDT) with methyl aminolevulinate (MAL),” *Dermatologie (Heidelb.)*, vol. 75, no. 1, pp. 71–74, 2024.

[11] D. Ferguson, A. Perry, M. E. Wood, P. G. Winyard, and M. Whiteman, “Potentiation of methyl aminolevulinate (MAL)-induced photodynamic therapy (PDT) killing of skin cancer cells by mitochondria-targeted hydrogen sulfide (H2S) donors,” *Free Radic. Biol. Med.*, vol. 76, p. S135, 2014.

[12] G.-R. Xu, M. Yan, Z. Huang, Y. Ye, and Y.-P. Song, “Corrigendum to ‘Correlation of retinal curvature with ocular biometry in patients with myopia’ [Photodiagnosis and Photodynamic Therapy 52 (2025) 104505],” *Photodiagnosis Photodyn. Ther.*, no. 104605, p. 104605, 2025.

[13] Y. Han, Y. Liu, B. Xu, L. Zhang, and L. Xu, “Comparison of small incision Lenticule extraction and Transepithelial photorefractive keratectomy in terms of visual quality and accommodation in Myopic patients,” *Photodiagnosis Photodyn. Ther.*, vol. 53, no. 104619, p. 104619, 2025.

[14] J.-H. Li *et al.*, “Corrigendum to ‘Comparative analysis of optic disc and macular microvasculature in children with anisometropic amblyopia before and after treatment’ [Photodiagnosis and Photodynamic Therapy volume 52 (2025) 1-10],” *Photodiagnosis Photodyn. Ther.*, no. 104601, p. 104601, 2025.

[15] R. Zhu, S. Yang, N. Yu, R. Zhang, and M. Wu, “Raman spectroscopy assisted diagnosis and photodynamic therapy efficacy evaluation of actinic keratosis: Case report,” *Photodiagnosis Photodyn. Ther.*, vol. 53, no. 104624, p. 104624, 2025.

[16] N. Alvarez and A. Sevilla, “Current advances in photodynamic therapy (PDT) and the future potential of PDT-combinatorial cancer therapies,” *Int. J. Mol. Sci.*, vol. 25, no. 2, p. 1023, 2024.

[17] S. L. Marcus and M. P. de Souza, “Theranostic uses of the heme pathway in neuro-oncology: Protoporphyrin IX (PpIX) and its journey from photodynamic therapy (PDT) through photodynamic diagnosis (PDD) to sonodynamic therapy (SDT),” *Cancers (Basel)*, vol. 16, no. 4, p. 740, 2024.

[18] R. R. Allison, Z. Huang, I. Dallimore, and K. Moghissi, “Tools of clinical Photodynamic Therapy (PDT): A Mini compendium,” *Photodiagnosis Photodyn. Ther.*, vol. 46, no. 104058, p. 104058, 2024.

[19] D. Thankachan *et al.*, “Enhanced tumor targeting with near-infrared light-activated indocyanine green encapsulated in covalent organic framework for combined photodynamic therapy (PDT) and photothermal therapy (PTT),” *Dyes Pigm.*, vol. 221, no. 111812, p. 111812, 2024.

[20] S. Bourbour, A. Darbandi, N. Bostanghadiri, R. Ghanavati, B. Taheri, and A. Bahador, “Effects of antimicrobial photosensitizers of photodynamic therapy (PDT) to treat periodontitis,” *Curr. Pharm. Biotechnol.*, vol. 25, no. 10, pp. 1209–1229, 2024.

[21] V. M. Pillai *et al.*, “A perspective on the stimuli-responsive photoactivities of coumarin with a focus on redox-responsive photodynamic therapy (PDT),” *Dyes Pigm.*, vol. 224, no. 112006, p. 112006, 2024.

[22] A. N. Al-Jamal *et al.*, “Photodynamic Therapy (PDT) in drug delivery: Nano-innovations enhancing treatment outcomes,” *Health Sci. Rev. (Oxf.)*, vol. 14, no. 100218, p. 100218, 2025.

[23] N. Sultana, R. Pathak, S. Samanta, and N. Sen Sarma, “A comprehensive analysis of photothermal therapy (PTT) and photodynamic therapy (PDT) for the treatment of cancer,” *Process Biochem.*, vol. 148, pp. 17–31, 2025.

[24] G. Li *et al.*, “Advances in smart nanotechnology-supported photodynamic therapy for cancer,” *Cell Death Discov.*, vol. 10, no. 1, p. 466, 2024.

[25] Q. Chang, P. Wang, Q. Zeng, and X. Wang, “A review on ferroptosis and photodynamic therapy synergism: Enhancing anticancer treatment,” *Heliyon*, vol. 10, no. 7, p. e28942, 2024.

[26] X. Liu, Y. Lu, X. Li, L. Luo, and J. You, “Nanoplatform-enhanced photodynamic therapy for the induction of immunogenic cell death,” *J. Control. Release*, vol. 365, pp. 1058–1073, 2024.

[27] F. Akhtar, L. Misba, and A. U. Khan, “The dual role of photodynamic therapy to treat cancer and microbial infection,” *Drug Discov. Today*, vol. 29, no. 8, p. 104099, 2024.

[28] D. Aebisher, J. Szpara, and D. Bartusik-Aebisher, “Advances in medicine: Photodynamic therapy,” *Int. J. Mol. Sci.*, vol. 25, no. 15, p. 8258, 2024.

[29] E. Christensen *et al.*, “Guidelines for practical use of MAL-PDT in non-melanoma skin cancer,” *J. Eur. Acad. Dermatol. Venereol.*, vol. 24, no. 5, pp. 505–512, 2010.

[30] W. Qi, Q. Lv, L. Chen, S. Huang, H. Zhan, and Z. Huang, “Comparative study of photodynamic therapy (PDT) of cervical low-grade squamous intraepithelial lesion (LSIL),” *Photodiagnosis Photodyn. Ther.*, vol. 48, no. 104247, p. 104247, 2024.

[31] S. Vig, B. Gaitan, L. Frankle, and H. C. Huang, “Laser exposure systems for multiwell plate photodynamic therapy (PDT) treatments: Reactive oxygen species generation and photocytotoxicity,” *Photodiagnosis Photodyn. Ther.*, vol. 46, no. 104128, p. 104128, 2024.

[32] J. Gao, Y. Tian, Y. Li, F. Hu, and W. Wu, “Design strategies for aggregation-induced emission photosensitizers with enhanced safety in photodynamic therapy,” *Coord. Chem. Rev.*, vol. 507, no. 215756, p. 215756, 2024.

[33] W. Zhao *et al.*, “Photodynamic therapy for cancer: mechanisms, photosensitizers, nanocarriers, and clinical studies,” *MedComm*, vol. 5, no. 7, p. e603, 2024.
[34] L. Yu *et al.*, “Towards overcoming obstacles of type II photodynamic therapy: Endogenous production of light, photosensitizer, and oxygen,” *Acta Pharm. Sin. B.*, vol. 14, no. 3, pp. 1111–1131, 2024.
[35] Y. Li *et al.*, “A versatile cryomicroneedle patch for traceable photodynamic therapy,” *Adv. Mater.*, vol. 36, no. 36, p. e2400933, 2024.
[36] Y. Tang *et al.*, “Oxygen-independent organic photosensitizer with ultralow-power NIR photoexcitation for tumor-specific photodynamic therapy,” *Nat. Commun.*, vol. 15, no. 1, p. 2530, 2024.
[37] M. B. Quaye and G. Obaid, “Recent strides in macromolecular targeted photodynamic therapy for cancer,” *Curr. Opin. Chem. Biol.*, vol. 81, no. 102497, p. 102497, 2024.
[38] X. Y. Ng *et al.*, “Ruthenium(II) polypyridyl complexes as emerging photosensitisers for antibacterial photodynamic therapy,” *J. Inorg. Biochem.*, vol. 250, no. 112425, p. 112425, 2024.
[39] S. Zeng *et al.*, “NIR-II photoacoustic imaging-guided oxygen delivery and controlled release improves photodynamic therapy for hepatocellular carcinoma,” *Adv. Mater.*, vol. 36, no. 4, p. e2308780, 2024.
[40] A. Grebinyk *et al.*, “Molecular and nanoparticulate agents for photodynamic therapy guided by near infrared imaging,” *J. Photochem. Photobiol. C: Photochem. Rev.*, vol. 58, no. 100652, p. 100652, 2024.
[41] R. Yavel, J. S. Overcash, J. Zhi, D. Cutler, and J. Fang, “25935 Phase I maximal use pharmacokinetic study of tirbanibulin ointment 1% in subjects with actinic keratosis (AK),” *J. Am. Acad. Dermatol.*, vol. 85, no. 3, p. AB76, 2021.
[42] A. Blauvelt, S. Kempers, S. Forman, E. Lain, and S. Bruce, “Tirbanibulin ointment 1%, a novel inhibitor of tubulin polymerization and src kinase signaling , for the treatment of actinic keratosis (AK): Results from two pivotal phase III studies,” *SKIN J. Cutan. Med.*, vol. 4, no. 5, p. s63, 2020.
[43] A. Blauvelt *et al.*, “Tirbanibulin ointment 1% for actinic keratosis (AK): Pooled data from two phase 3 studies,” *SKIN J. Cutan. Med.*, vol. 4, no. 6, p. s121, 2020.
[44] P. Chmiel, M. Kłosińska, A. Forma, Z. Pelc, K. Gęca, and M. Skórzewska, “Novel approaches in non-melanoma skin cancers-A focus on Hedgehog pathway in basal cell carcinoma (BCC),” *Cells*, vol. 11, no. 20, p. 3210, 2022.
[45] A. Darjani *et al.*, “Association between serum vitamin D levels and basal cell carcinoma (BCC),” *J. Ski. Stem Cell*, vol. 4, no. 3–4, 2017.
[46] Department of Plastic Surgery, Civil Hospital, Dow University of Health Sciences (DUHS), Karachi, Pakistan. *et al.*, “Patient satisfaction after basal cell carcinoma (BCC) excision in head and neck region followed by reconstruction with loco regional flaps and full thickness skin graft,” *Nat. J. Health Sci.*, vol. 10, no. 1, pp. 15–19, 2025.
[47] A. Sharma, R. Khanna, P. Khanna, R. Khanna, and S. Khanna, “A case series analysis of basal cell carcinoma (BCC): Not the deadliest but certainly the most destructive form of skin cancer,” *Acta Med. Int.*, vol. 11, no. 3, pp. 263–268, 2024.
[48] I. A. Ningtyas, Densy Violina H, and Y. Octavianda, “Basal cell carcinoma (BCC) with risk factors of exposure to burns: A case report study,” *Archives of The Medicine and Case Reports*, vol. 5, no. 3, pp. 728–735, 2024.
[49] E. Christensen *et al.*, “New, simplified versus standard photodynamic therapy (PDT) regimen for superficial and nodular basal cell carcinoma (BCC): A single-blind, non-inferiority, randomised controlled multicentre study,” *PLoS One*, vol. 19, no. 3, p. e0299718, 2024.
[50] S. Abatli, M. Hasan, S. B. Sholi, A. Qashoo, and I. Maqboul, “Recurrent basal cell carcinoma (BCC) of the forearm: A case report,” *Cureus*, vol. 15, no. 6, p. e40247, 2023.
[51] J. S. Deutsch, K. M. Schenk, A. Soni, E. Lipson, and J. Taube, “1579 LAG-3 expression in advanced basal cell carcinoma (BCC) and tumor regression following combined PD-1/LAG-3 blockade,” *J. Invest. Dermatol.*, vol. 143, no. 5, p. S271, 2023.
[52] “Azathioprine/Prednisone: Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC): case report,” *React. Wkly.*, vol. 2032, no. 1, pp. 80–80, 2024.
[53] A. M. Samia, J. M. Nenow, and P. Boyer, “A case of metastatic basal cell carcinoma (BCC) with spinal and pulmonary metastases treated with vismodegib, sonedigib, and radiotherapy,” *Cureus*, vol. 14, no. 3, p. e23273, 2022.